Our response to COVID-19
In 2020, a new strain of a group of viruses called coronaviruses - identified by the World Health Organisation as the novel coronavirus SARS-COV-2, which causes the disease COVID-19, has turned into a global pandemic.
In response, the Janssen Pharmaceutical companies of Johnson & Johnson mobilised to begin development of a preventative coronavirus vaccine with the potential to protect people against the disease.
"The company has a long-standing commitment to fight emerging epidemics. We stand ready to support global efforts where it may make a difference. Developing preventive solutions for those who are most vulnerable to infectious diseases like these is our top priority. We have established technologies and facilities that enable us to create, test and scale up production for potentially transformational vaccines. Our experience in helping to address epidemics, coupled with our expertise in respiratory illnesses, uniquely positions us to address the latest coronavirus outbreak".
- Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson.
Watch the below video and meet some of the inspiring Johnson & Johnson scientists working on the novel coronavirus vaccine at the company's labs in Leiden, The Netherlands.
As a global leader in health, our top priority remains our patients, customers and employees.